CN Spring 2007

A Q UA RT E R LY P U B L I C AT I O N O F C I T Y O F H O P E
VO LU M E 1 8 N U M B E R 2 S P R I N G 2 0 07
CityNews
Whats in your DNA?

Nature and nurture link to cancer risk
A lasting legacy: Diana Chudacoff Levin Stem cells deliver a one-two punch
Leadership Messages
Honoring decades of inspirational service

During the past three years, I have been honored to serve as chair of City of Hopes board of directors. This experience has allowed me to work with many talented and visionary volunteer leaders who share the same passion for furthering the institutions mission. As my tenure draws to a close, I want to acknowledge six devoted supporters whose terms as board members also will soon end: Israel Izzy Freeman, Robbin Itkin, Stephen Kass, Claire Rothman, Joseph Sanford and immediate past chair Jack Suzar. These committed individuals have contributed their invaluable time, expertise and financial support to advance City of Hopes growth and development. Reflecting their unwavering dedication to the institution, all of these longtime volunteers will remain engaged as active City of Hope supporters in new roles, such as fundraisers, board committee members and goodwill ambassadors, so that their relationships and history with the organization will continue to benefit the fight against life-threatening diseases. Many volunteers stand alongside these leaders, guiding and encouraging City of Hopes evolution into a world-renowned biomedical research institute. In coming years, the contributions of the auxiliary movement will continue to play a key role as we aspire to expand the reach of our work to benefit even more lives. Chapter members vision, funding and advocacy will serve to further City of Hopes current research and clinical strengths, as well as expand existing programs. On behalf of the entire City of Hope family, I wish to thank our retiring board members for their steadfast support and continued commitment to City of Hopes mission to improve and save lives. Philip L. Engel
Chair, City of Hope Board of Directors
Exploring the macro and micro

With a few strokes of a computer keyboard, todays online satellite imagery tools allow us to change our geographic perspective in seconds. We can view Earths surface as if from space, then zoom in on our nation, our city, our neighborhood and even our rooftop. That seamless journey between macro and micro has parallels in science and medicine. At City of Hope, we take the same sweeping look at cancer, from its impact on the population to its roots deep in the body. Cancer affects the most subtle aspects of our cells, where genes reside. Mutations in genes passed down through generations can raise the risk of certain cancers. Other genetic defects can happen over the course of a lifetime, and these errors may accumulate until cells turn cancerous and grow unchecked. As you will learn in this issue, City of Hope researchers investigate this world on a minute scale the molecular and genetic levels creating critical knowledge and laying the foundation for therapies. From there, researchers widen their scope. They help create and improve genetic risk assessments, which can identify people at greater risk for cancer so people may take steps to prevent it. Others investigate how genetics influence disease patterns among ethnic groups, ultimately designing interventions for these populations. This spectrum of cancer research from micro to macro is one thing that characterizes us as a Comprehensive Cancer Center, a special designation from the National Cancer Institute garnered by only 39 institutions nationwide. City of Hope supporters should take great pride in this designation, since contributions from donors and volunteers have helped us achieve this status. The institutions board of directors, in particular, serves to steer us along this path, and Philip L. Engel, the boards retiring chair, has been instrumental in our quest to reach even greater heights. I thank and salute him for his generous service, and wish him well as he leaves his post. Michael A. Friedman, M.D.
President and Chief Executive Officer
City of Hope, an innovative biomedical research, treatment and educational institution, is dedicated to the prevention and cure of cancer and other lifethreatening diseases, guided by a compassionate patient-centered philosophy, and supported by a national foundation of humanitarian philanthropy.
City of Hope
City News is published quarterly for donors, volunteers and friends of City of Hope.
BRENDA MACEO Senior Vice President, Communications KEVIN KOGA Associate Vice President, Communications
STEVE KIRK Editor ALICIA Di RADO Story Editor KIM HOSOZAWA Associate Director, Creative Services
CARMEN R. GONZALEZ JENNIFER HEALY PAT KRAMER SHAWN LE KATHLEEN ONEIL FRAN RIZZI H. CHUNG SO MARK WHEELER Writers
CITY NEWS SPRING 2007
CityNews
A Q U A R T E R LY P U B L I C AT I O N O F C I T Y O F H O P E
VOLUME 18 NUMBER 2 SPRING 2007
Whats in your DNA? Nature and nurture link to cancer risk

Just as some genes determine eye color and height, others seem to increase the risk of cancer and other diseases. Researchers at City of Hope are seeking ways to identify who may be most vulnerable, so steps may be taken to prevent illness or catch it early.
Good tasting and good for you
A common mushroom may help prevent breast cancer by suppressing estrogen production in postmenopausal women.
10 12
Delivering a one-two punch
Specially engineered HIV-fighting genes also may eradicate the lymphoma that arises in many HIV-positive patients.
A tiny idea with huge implications
A drug measuring less than half the size of a strand of human hair can pass through even the smallest blood vessels, delivering potent chemotherapy to tumor cells.
14
Vaccine may ward off CMV invaders
A cytomegalovirus (CMV) vaccine created at City of Hope may bring immunocompromised patients protection against pneumonia and other diseases.
18
Biotech entrepreneur joins City of Hope board
19
A lasting legacy in immunotherapy: Diana Chudacoff Levin
26
Building a future of hope: The 2007 National Convention
29
An ounce of prevention: Keeping healthy
CITY NEWS SPRING 2007 I 1
2 I CITY NEWS SPRING 2007
WHATS IN YOUR
Studying nature and nurture links to cancer risk
DNA?
By Kathleen ONeil
The genetic guessing game starts shortly after a babys birth. Hes got your blue eyes. She inherited your moms button nose. He got his dads curly hair.
Anyone attending a parent-child night at school can quickly see the role genes and inheritance play in human physical traits. Ear shape, skin color, height these and so many other obvious features are passed
ILLUSTRATIONS: RAFAEL LOPEZ
along from mother and father to son or daughter.
Yet just as people inherit their parents physical features, they also inherit their less-noticeable genetic characteristics. Human DNA preserves the blueprints for astounding capabilities developed over hundreds of generations, such as sight, walking upright and higher reasoning. However, those inherited genes may also include some that are not so helpful and some that may be downright harmful including genes that increase the risk of cancer and other diseases. Today, researchers at City of Hope are investigating just how these not-so-obvious genes increase cancer risk. They also seek ways to identify who is at increased risk of disease so they can take steps to prevent it or catch it early. Some also look beyond the genetic make-up of individuals looking instead at bigger groups to learn how cultural, genetic and social differences may contribute to risk and survival among various ethnic populations.
What links within

Each cell in the human body contains 25,000 to 35,000 genes. Genes line up in structures called chromosomes. The nucleus of human cells contains 23 pairs of chromosomes half inherited from
the mother, the other half from the father. When genes are altered or mutated, they may cause disease. Sometimes parents pass along altered forms of genes to their children. Sickle cell anemia, for example, arises in children due to genetic mutations inherited from their parents. Other mutations in genes come not from parents, but from genetic hiccups that can happen during the course of a lifetime. Genes can become altered due to exposures to toxins in the environment, such as asbestos, chemicals and secondhand smoke, for example. Personal lifestyle habits and other factors, including sun exposure, lack of exercise and a poor diet, also may contribute. Possessing an inherited mutation is like a baseball player starting out with one strike against him before he even steps up to the plate. Sometimes it does not take many more mutations to advance a cell to a cancerous stage. More than 100 known genes are thought to increase a persons risk of cancer or other diseases, including breast, ovarian and colon cancer and endocrine disorders, said Theodore Krontiris, M.D., Ph.D., executive vice president of Medical and Scientific Affairs, director of City of Hope Comprehensive Cancer Center and professor of Molecular Medicine. Mutations can lead to cancer in a few ways. They can prevent the repair of DNA damage, which can then lead to a buildup of defects, some of which overstimulate cell growth. Some turn off controls for cell maturation, while others keep damaged cells from preventively self-destructing before they go awry. Each cancer has its own combination of mutations that give rise to it and keep it going even cancers that are found in the same tissue type. Krontiris and his colleagues have
studied genes associated with an increased risk of prostate cancer by looking at the DNA from men with prostate cancer whose brothers also had the disease. They identified a new mutation that appears to only increase the risk of prostate cancer when a man inherits the mutation from both parents. The finding could eventually lead to new tests for prostate cancer risk. That mutation may illuminate the significance of introns, small sections of DNA that were thought to be extra, unused genetic bits a sort of filler in the genetic code. Krontiris and his colleagues are studying introns to understand how they affect the function of active genes around them. They are finding that introns act indirectly and might contribute to cancer, diabetes, hypertension and neurodegenerative disorders. Its still too early to understand how they work, Krontiris said. While we think
More than
100 known genes are thought to increase a persons risk of cancer or other diseases.
we know what the genes do, were not sure how gene variations cause elevated risks of cancer. Most people who develop cancer do not have an inherited genetic mutation. Instead, they accumulate mutations from
environmental exposures, lifestyle and the passing of years. But for the 5 to 10 percent of people who have genes known to increase cancer risk, the odds can loom particularly large. While the risk of getting cancer
from having inherited cancer genes for the total population is small, the risk for people who carry these genes is much higher, said Jeffrey Weitzel, M.D., director of the Department of Clinical Cancer Genetics and associate professor in the
Division of Medical Oncology & Therapeutics Research. For example, women without a genetic predisposition for breast cancer have about a 2 percent risk of developing cancer by age 50. But, women who carry a mutation in one of the BRCA genes mutations known to be linked to breast and ovarian malignancy have a 20 percent risk of developing breast cancer by age 40. That rises to a 50 percent chance by age 50, and as much as an 85 percent risk over their entire lifetimes. That points out the need to identify who is carrying the genes, so they may be screened and consider preventive therapies to help reduce their risk, Weitzel added.
The family tree

Genetic screening is not for everyone, noted Weitzel. Experts say prime candidates for the testing include those who have several close relatives with a certain type of cancer, as well as women or men who develop a gender-specific cancer but who do not have enough relatives of that gender to determine if the disease runs in the family. Testing even after cancer diagnosis can help patients prevent future cancers, Weitzel said. In a study published in 2003, he and his colleagues found that when women newly diagnosed with breast cancer underwent genetic testing to determine their inherited risk, they were more likely to select treatment that reflected that risk. The seven women in the study whose tests indicated they had a high risk of recurrence all chose to have bilateral mastectomies rather than more conservative treatment. If a woman is a BRCA carrier, the chance shell develop another cancer in
the next 10 years is 40 percent, and most women have no desire to go through surgery, radiation and chemotherapy again. It gives them a chance to practice both therapy and prevention, Weitzel said. And if women who know their genetic risk share that information with family members, they can encourage family members who also may be at higher risk to be vigilant about getting screened, he added. Recent research indicates that mutations in more than 500 genes may be involved in human cancers, and about 120 of them actually drive cancer development. According to cancer genome researchers, mutations in 1 percent of all human genes are linked to cancer. Of these, about 20 percent can be inherited, while the rest can be acquired through environmental or other exposures. (About 10 percent can either be inherited or acquired.) As researchers comb through the human genome, the list of known cancer-linked genes will continue to grow. Garry Larson, Ph.D., associate research scientist in the Division of Molecular Medicine, Weitzel and others at City of Hope are working to develop tests for such gene mutations in breast cancer. By comparing genetic material from tumors from sisters with breast cancer, they hope to find more inherited breast cancer gene mutations. These discoveries change lives. When 45-year-old City of Hope breast cancer patient Merry Rogers was diagnosed with the disease, she did not believe family history could be to blame. Since her mother did not develop breast cancer, she thought, genetics could not be playing a role. But Rogers later learned that her fathers mother and several other relatives
Most people who develop cancer do not have an inherited genetic mutation. Instead, they accumulate mutations from environmental exposures, lifestyle and the passing of years.
on her fathers side had died of breast cancer. She got tested for BRCA genes. When results confirmed she had the BRCA1 gene mutation, she felt relieved. It sounds silly, but I was really happy to know that I had the gene, because then I could explain to myself why I got cancer, Rogers said. She shared the results with her two sisters and brother, and encouraged them to be tested, as well. Im happy because I think Im leaving a legacy for my nephews, so that three or four generations from now, they can be more aware of the risk, Rogers said. Based on the results, she decided to have a more radical surgery to nearly eliminate her risk of breast cancer. I used to think that Id die of cancer that it would eventually come back, she said. Now I think Id be really surprised if I got it again. I think Ill live to be 90.
Extended families
While parents contribute their offsprings genetic traits, their race and ethnicity tie their children to those larger groups, too. Those ancestral histories can influence risk, as researchers have found that certain cancers occur more often or are
more lethal in certain groups. Gene mutations that occurred early in the history of certain races and ethnic groups are passed on, so many members of those populations now carry them. For instance, studies show descendents of Ashkenazi Jews are more likely to carry BRCA gene mutations, which increase the risk of breast cancer in both women and men. Ashkenazi Jews trace their heritage to the medieval Jewish communities that lived near the Rhine river in Germany. Weitzels lab also has found a previously unrecognized gene linked to people of Mexican descent that is a variation on the Jewish genes. He suspects its origins may stretch back to Jewish people who fled to Mexico during the Spanish Inquisition.
Ancestral histories can influence risk. Gene mutations that occurred early in the history of certain races and ethnic groups are passed on.
This finding may explain in part why certain Latinas are at higher risk of breast cancer, despite Latinas overall lower risk compared to whites. Researchers found that 31 percent of Latinas with breast cancer who were screened between 1998 and 2004 at City of Hope had genetic mutations that increased their risk of breast cancer. Other races and ethnicities have different mutations that similarly increase the risk of breast cancer. Race and ethnicity also influence survival rates in patients with lifethreatening diseases. Smita Bhatia, chair of the Division of Population Sciences and associate director of the Cancer Control and Population Sciences Program, is researching the influence of race and ethnicity, as well as socioeconomic status, on the survival of children treated for leukemia. Eighty percent of children diagnosed with acute lymphoblastic leukemia the most common form of childhood leukemia live at least five years after treatment, depending on the severity of their disease. However, children in certain ethnic groups appear to have a better chance of surviving and avoiding recurrence than others. Children of Asian descent had the highest rates of survival at five years, with no relapse in 75 percent of those studied, followed by whites and Latinos. Blacks had the lowest rates of survival without relapse, at about 62 percent. The difference, Bhatia said, might be genetic or physiologic. Social factors also come into play. Possible reasons include differences in the way children of different ethnicities respond to drugs, varying levels of access to health care that could lead to later-stage diagnoses, or
differences in how well the children and their parents are able to comply with taking medication and receiving care. Researchers must perform rigorous studies to separate true genetic factors from environmental and social ones. Bhatia recently began a five-year study to determine which of those factors influence survival. She will analyze blood drawn from children and young adults up to age 22 to see how well their bodies metabolize therapeutic drugs. In addition, researchers will survey childrens pilltaking habits and provide smart pill bottles that record each time they are opened to record compliance. Its important for the children to take their drugs as prescribed. If they dont, it really increases their chance of recurrence, Bhatia said. But if theyre taking them, and its not helping them as much, this will help us to understand what is going on physically to create that difference. Understanding those connections between social, family and genetic predispositions to cancer and other diseases is the first step in finding better ways of treating them, and eventually preventing them. I I I
MUSHROOMS MAY SUPPRESS ESTROGEN, DETER BREAST CANCER

By Kathleen ONeil
A breast cancer fighter may be lurking in the aisles of the local supermarket. White button mushrooms, the garden-variety fungi so common in the kitchen, may help prevent breast cancer by suppressing estrogen production in the body, according to a study led by City of Hope researchers.
The mushrooms may wield their greatest preventive effect on postmenopausal women by blocking the important enzyme known as aromatase, according to a study published in the recent issue of the journal Cancer Research. Aromatase is a substance that helps the body make estrogen. We decided to look at mushrooms because we know that synthetic aromatase inhibitors can prevent breast cancer recurrence, said Shiuan Chen, Ph.D., director of the Department of Surgical Research and lead author of the study. About 60 percent of the breast cancers in premenopausal women and 75 percent of those in postmenopausal women depend on estrogen to grow; controlling estrogen levels in the body can help limit or prevent cancer growth. Inhibiting aromatase is an important way
ILLUSTRATION: BECKY HEAVNER
to control estrogen levels among postmenopausal women. Before menopause, the brain governs the bodys estrogen levels by controlling the ovaries production of estrogen from aromatase. The brain can override attempts to inhibit aromatase in these women. But after menopause, estrogen primarily is created in fat and other tissues, independent of control by the brain. Consequently, blocking aromatase blocks estrogen production. Aromatase is normally expressed in tissues such as ovary, placenta, fat and bone. The substance also is expressed at higher levels in breast cancer tissue than in normal breast tissue. The researchers tested seven vegetable extracts for aromataseinhibiting activity. They found that mushrooms had the most effective anti-aromatase effect due to one phytochemical: conjugated linoleic acid. They were surprised to find that mushrooms contain conjugated linoleic acid, a compound previously shown to have anticancer properties, because it is mainly present in animal-based foods. They found celery has a moderate effect on aromatase, while green onion, carrot, bell pepper, broccoli and spinach extracts did not significantly reduce aromatase levels. The group then tested other mushrooms, and found that whitestuffing mushrooms had the strongest effect. Shiitake, white button, portobello, crimini and baby button mushrooms also had significant inhibitory effects on aromatase, even when cooked. After confirming the presence of anti-aromatase chemicals in white button mushrooms, the researchers used laboratory and mouse studies to confirm that the anti-aromatase compounds
could stop the growth of breast cancer cells. They found that mice that were fed mushroom extract had a 58 percent reduction in breast tumor growth. Chen said the research team is now carrying out similar studies on the effect of anti-aromatase compounds from food on prostate cancer. They also are planning a clinical trial to test the effect of mushrooms on estrogen levels in women. The idea of exploring foods for cancer prevention is very important, because prevention is much better than treating a disease, Chen said. You dont need a strong effect to cause cancer prevention. Eating 100 grams (about 3.5 ounces) or even less of mushrooms per day could have an effect on preventing new breast cancers. Other City of Hope researchers included Sei-Ryang Oh, Ph.D., Sheryl Phung, Gene Hur, Jing Jing Ye, Sum Ling Kwok, Lynn Adams, Ph.D., and Dudley Williams, Ph.D., as well as Gayle Shrode, Ph.D., and Martha Belury, Ph.D., of Ohio State University. The research was supported by the California Breast Cancer Research Program, the National Institutes of Health and the Mushroom Council. I I I
Shiuan Chen
MARKIE RAMIREZ
R E S E A R C H
AND GOOD FOR YOU,TOO
A N D
GOOD TASTING
T R E AT M E N T
DELIVERING A
By Kathleen ONeil
Sometimes the bodys defenses can readily fight off infections, pummeling cold- and flu-causing viruses into submission. But at other times a virus gets the upper hand, and the bodys immune system cannot battle invaders on its own.
That is when City of Hope researchers step in. Scientists at the institution are investigating a method to fight HIV, the virus that causes AIDS, with genetically modified stem cells. But that is not all. At the same time it seeks to knock down virus levels, the technique aims to eradicate the lymphoma that arises in many HIV-positive patients. The treatment would be the first to use specially engineered, HIV-fighting genes that are inserted into patients own harvested stem cells. The cells would then be reinfused into HIV-infected patients during a bone marrow transplant. If successful, the new treatment could allow patients bodies to produce HIV-resistant white blood cells indefinitely. This may be a way to control the patients HIV while still allowing them to have a successful bone marrow transplant to treat their cancer, said John Zaia, M.D., chair of the Division of Virology at City of Hope and an investigator in the pilot study. Its especially exciting because if the method using stem cells works, it could be applied to many hematological diseases that have a genetic basis. Scientists presented the research at the 48th annual meeting of the American Society of Hematology in Orlando, Fla., late last year. Zaia now is awaiting approval for an upcoming trial at City of Hope that would
ILLUSTRATION: RANDY LYHUS
incorporate the anti-HIV therapy. Researchers at City of Hope and other institutions have shown that autologous stem cell transplants can benefit HIV-positive patients with lymphoma. City of Hope has performed autologous stem cell transplants on 28 HIV-positive patients with lymphoma since 1998. Autologous stem cell transplants involve harvesting stem cells from a patients blood, then reinfusing the cells into the patient after cancerous cells have been destroyed. Today, autologous stem cell transplants are standard therapy for lymphoma that cannot be cured by regular-dose chemotherapy alone. In this form of transplantation, the new stem cells develop into white blood cells, immune cells that form the bodys line of defense, after they are reinfused into the body. The constant destruction and production of immune cells in response to HIV is one reason HIV-positive people develop lymphomas at a much higher rate than uninfected people. Lymphomas are cancers of the lymphatic system, the network of lymph ducts and nodes where immune cells circulate. City of Hope and the Food and Drug Administration have not yet completed review of the proposed study. But upon study approval, scientists would take the stem cells of patients with HIV and lymphoma one step further: They would insert HIV-fighting genetic material into the cells before reinfusing them into the body. Scientists use a lentivirus to carry the gene segments into the stem cells. Earlier clinical trials involving HIVrelated lymphoma patients provided stem cells treated with one type of HIV-fighting genetic material. Their stem cells contained the anti-HIV gene for a short time, but after a few months the cells died off, presumably because the genetically treated stem cells were unable to replicate. But researchers hope new advances will allow the body to
keep producing HIV-resistant white blood cells, Zaia said. The new trial would mark the first time that scientists will use three different antiHIV segments at one time, which they hope will prevent HIV from developing resistance. The virus can mutate around any one element, but its hard to mutate around three things, he said. The method has already shown promise in preclinical studies conducted by City of Hope researchers working with Ramesh Akkina, Ph.D., of Colorado State University, and colleagues. This could provide the optimal chance of knocking down the virus long-term for patients with high-risk AIDS-related lymphomas, Zaia said. The method cannot completely rid the body of every trace of HIV, however, since the virus lies deep in lymph nodes and other parts of the body, he said. The pilot study also included these City of Hope researchers: principal investigator Amrita Krishnan, M.D., associate professor and physician in the Division of Hematology & Hematopoietic Cell Transplantation (HCT); Stephen J. Forman, M.D., the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation and chair of the Division of Hematology & HCT; Jiing-Kuan Yee, Ph.D., professor in the Division of Virology; and John Rossi, Ph.D., chair in the Division of Molecular Biology. I I I
John Zaia and Amrita Krishnan
ALICIA DI RADO
R E S E A R C H
ONE-TWO PUNCH
A N D
T R E AT M E N T
T R E AT M E N T
A TINY IDEA
A N D
WITH
R E S E A R C H
HUGE IMPLICATIONS
IN THE FIGHT AGAINST CANCER
ILLUSTRATION: JEFFREY PELO
By Mark Wheeler
Use tiny, engineered molecules as high-tech delivery trucks to carry potent chemotherapy drugs to tumor cells? Although it may sound like a fantastic voyage, such a scenario is very real and happening today in laboratories at City of Hope.
City of Hope researchers have opened a clinical trial of a new nanomedicine to fight cancer. Although it is too early to report results, researchers are enthusiastic about the innovative technologys potential. The clinical trial combines a synthetic polymer (a long molecule) and camptothecin, a very powerful chemotherapy, into a new experimental drug called IT-101. Researchers designed the polymer to safely deliver the camptothecin directly into tumor cells and provide slow release of the drug once there. Physicians hope the method fights tumors more powerfully than traditional chemotherapy with fewer accompanying side effects, according to Yun Yen, M.D., Ph.D., director of the Department of Clinical and Molecular Pharmacology and the trials lead investigator. The phase I clinical trial is a collaboration with Insert Therapeutics Inc., a company founded by a chemical engineer from the California Institute of Technology who conceived the idea for the nanodrug after seeing chemotherapys effects firsthand. The engineer Mark Davis, Ph.D., the Warren and Katharine Schlinger Professor of Chemical Engineering at Caltech is now part of City of Hope Cancer Centers Experimental Therapeutics Program, as well as a member of the National Academy of Engineering and the National Academy of Sciences. But in 1996, he visited City of Hope for much different reasons. Diagnosed with breast cancer, Davis wife, Mary, was under the care of City of Hopes Stephen J. Forman, M.D., the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation and a physician in the Division of Medical Oncology & Therapeutics Research. While undergoing treatment, she suffered the side effects common to patients on chemotherapy, including hair loss, loss of appetite and nausea. Davis vowed to find a better way to deliver therapy. Over three months in the mid-1990s, while his wife was in treatment, Davis pored over materials in City of Hopes Graff Library to learn about cancer therapies and began to develop his strategy. He used his expertise in creating new materials molecule by molecule, ultimately building his first nanomedicine for cancer from scratch. But he could not bring his idea to the clinic without knowledgeable collaborators. Davis founded Insert Therapeutics to develop the invention into a product that could be used in humans. Investigators at Insert Therapeutics showed the potential of this new nanomedicine in animals, and Yen worked with company investigators to design the clinical trial that was eventually approved by the Food and Drug Administration. These partnerships brought an inspiration from the patients bedside into the lab and back to the bedside. Now, the resulting nanomedicine developed by Insert Therapeutics is in a human clinical trial only at City of Hope. As Yen explains, delivering chemotherapy always has been problematic because side effects limit the dosage that physicians can safely give patients. But minimizing these side effects gives us greater flexibility in the dosing frequency, said Yen, also a professor of medical oncology at City of Hope. It also allows us to use combinations of drugs that were previously limited by accumulated toxicity. The result could be used to provide more effective therapies. The drug, IT-101, measures about 35 nanometers in length. (One nanometer equals one-billionth of a meter, and a single strand of human hair is about 80,000 nanometers across.) That is tiny enough to pass through even the smallest blood vessels to get to where cancer has metastasized, and then enter the cancer cells. Size is critical, according to Davis. The polymerbased nanoparticle is small, but its huge compared to the tiny molecules that compose a drug. Comparatively speaking, its the difference between the size of a soccer ball the drug molecule and about half the size of the Goodyear blimp, the polymer device, he said. Make the nanomedicine too small and it will be quickly excreted from the body. Conversely, if it is too large, it wont allow for good penetration into the tumors. The resulting particle is designed to access cancer cells, target growth processes and shut them down by effectively delivering a large payload of drug. Both Davis and Yen agree such nano-sized medicines have the potential to ultimately become the medical standard in cancer therapy. This is a perfect example of linking clinical expertise with research expertise to push drug development and cancer treatment to more efficient levels, said Yen. Ultimately, this collaboration can only benefit patients through more targeted drug dosages and, hopefully, the virtual elimination of side effects. I I I Yun Yen
KAMINSKY PRODUCTIONS
T R E AT M E N T
Promising vaccine may ward off CMV invaders

By Shawn Le
R E S E A R C H
A N D
The human body plays host to millions of bacteria and viruses in a lifetime. Some are unwelcome invaders, like those that cause colds and flus. Many others are beneficial, like the bacteria lining the digestive system that help process food. Still others simply exist, doing no harm until they find their opportunity.
Cytomegalovirus (CMV) is one such microbe. Sadly, CMV often exploits immunocompromised people, such as cancer patients treated with bone marrow transplantation. However, a CMV vaccine created at City of Hope, and recently approved by the Food and Drug Administration for its first human clinical trial, might bring vulnerable patients much-needed protection. Don J. Diamond, Ph.D., director of the Laboratory of Vaccine Research, has begun a phase I clinical trial to test the vaccine. The vaccine consists of a combination of two small molecules called peptides. One peptide acts as a vehicle or general stimulant for the other, which is a peptide specific to CMV. Researchers believe the vaccine will stoke the body to boost immunity against CMV. This clinical trial is the culmination of close to a decade of research and development into the CMV peptide, said Diamond. Our goal is to replace the current standard therapy, ganciclovir, which is toxic, with the less-toxic vaccine. Diamonds work with the CMV peptide began in 1997 under the aegis of the hematology program, directed by Stephen J. Forman, M.D., the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation. CMV is a common type of herpes virus that infects from 50 to 80 percent of adults in the United States by age 40 and a similar percentage worldwide. It causes no symptoms in most healthy adults and usually remains dormant. But in people with weakened or compromised immune systems, such as patients who have undergone hematopoietic cell transplants, CMV can reactivate and cause lifethreatening pneumonia and other diseases. In the beginning days of the bone marrow transplantation program, CMV infection was the cause of the majority of patient deaths, said Diamond. To control the possibility of CMV infection more effectively with fewer side effects, perhaps even eliminate it, would be a great benefit to all transplantation patients. City of Hope is enrolling healthy volunteers who either have or have not had a CMV infection to participate in the one-year study of two different forms of the CMV peptide vaccine. The safety trials will determine which form of the vaccine has milder side effects, and possibly hint at which one is preferable for patients. The vaccine is specific to people who carry or react to a specific type of molecule (or human leukocyte antigen type) found in about 40 percent of the transplant population. If were successful with this first target antigen, then we can develop and test versions that will cover up to 80 percent of the transplant population, said Diamond. The vaccines implications may eventually reach beyond hematopoietic cell transplant patients, as well. Others vulnerable to CMV include patients susceptible to vascular disease, those in need of a lung, liver or kidney transplant, and those with HIV. Babies infected with CMV at birth or when very young, too, may
Immunofluorescence shows the presence of CMV in a specimen of human embryonic lung.
M
face disabilities and might one day benefit from this or other vaccines in development. Collaborators on the vaccine project include John A. Zaia, M.D., professor and chair of the Division of Virology and principal investigator of the phase I clinical trial, Corinna La Rosa, Ph.D., assistant research scientist, the General Clinical Research Center at City of Hope, and the nursing staff in the Department of Transfusion Medicine. When the vaccine becomes available to City of Hope transplant patients, the Division of Hematology & Hematopoietic Cell Transplantation, under Formans direction, will supervise the clinical trial, Diamond said. To find out more information about the clinical trial or how to participate, call 877-482-HOPE (4673) or visit City of Hopes clinical trials Web site at clinicaltrials.coh.org. I I I
MEDICAL RESOURCES PLUS
Don J. Diamond
DARRIN S. JOY
CDC/CRAIG LYLERLA
Finding the truth within

Improving ways to assess a womans risk for breast cancer
By Pat Kramer and Alicia Di Rado
Information is power, and for women information may hold the power to save lives. Genetic counselors can gather information about their families and backgrounds that can shed light on womens realistic, personal risks of developing breast cancer. City of Hope researchers are helping make these risk assessments even more accurate.
The researchers have found that using measurements of a womans breast density, as well as her family history, age and other similar factors, may improve the ability to predict her risk of developing breast cancer over todays standard risk-assessment models. City of Hope researchers and their colleagues from the University of Washington and the Fred Hutchinson Cancer Research Center recently reported these findings based on a sample from a study of more than 13,000 women considered at high risk for breast cancer. The researchers are investigating ways to determine womens true risk of developing cancer so that women and their physicians can take better steps to prevent it. Research has shown that women with certain patterns of dense breast tissue may have as much as a six-fold higher risk of developing breast cancer as other women, explained City of Hopes Melanie Palomares, M.D., assistant professor of Medical Oncology and Population Sciences and the studys lead author. Breast density can be observed through
The density of breast tissue can range widely. Mammography shows highly dense tissue, left, and tissue of low density, on the right.
mammography and may be a measure of breast cell proliferation. Researchers believe the more breast cells multiply over a lifetime, the greater the breast cancer risk. At the same time, health professionals today rely on other noninvasive clinical tools to predict a womans breast cancer risk. One commonly used tool is the Gail model, which incorporates age, family history, childbearing history, previous breast biopsies and similar factors into a formula to calculate risk. Palomares and colleagues compared risks using both the Gail model and breast density to understand the significance of each of the factors incorporated in the Gail model. They found that breast tissue was significantly denser in women with a 15 percent or greater lifetime risk of breast cancer, as determined by the Gail model, compared to women with less than a 15 percent risk. For comparison, the average woman has a lifetime risk of 12.5 percent. Each factor in the Gail model corresponded to some of the risk increase associated with dense breast tissue. But a striking 7 percent of the women deemed at high risk through mammographic density could not be explained by any of the risk factors currently included in the Gail model. Other factors must be at play, Palomares said. We found that when the two were correlated, the Gail model could not explain all the relationships between mammographic density and breast cancer risk, Palomares said. This shows the importance of including mammographic density in future settings of breast cancer risk and prevention. This also wields implications for prevention. Many of the factors that influence breast density, such as hormone replacement therapy, diet and weight, can be changed through lifestyle choices. These factors are not part of the Gail model. If women gain a better idea of the breast cancer risk they face, they may be
more encouraged to improve the risk factors they can control, Palomares said. In the future, more research must be done to improve how health professionals and researchers access digital mammograms and read breast density, Palomares said. The groups study was published in the journal Cancer Epidemiology Biomarkers & Prevention. Women in the study were part of the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trials site in Washington and were enrolled between 1992 and 1997. The National Cancer Institute funded the research. I I I
MELANIE PALOMARES
R E S E A R C H
A N D
T R E AT M E N T
T R E AT M E N T
Homing in on a deadly cancer

By Alicia Di Rado
R E S E A R C H
A N D
Frederic W. Grannis Jr., M.D., and Arnold Rotter, M.D., are hunting for a killer.
Todays most lethal cancer does not arise in the breast, nor in the prostate. The leading cancer killer is lung cancer, but physicians in City of Hopes Lung Cancer and Thoracic Oncology Program believe certain technological tools already available today can make it a little less deadly. Using spiral computed tomography, or CT, to routinely screen people at high risk for lung cancer can detect the disease early and increase the chance of cure, according to a study in the New England Journal of Medicine that included City of Hope researchers. Grannis and Rotter are part of the International Early Lung Cancer Action Program, or I-ELCAP, which published the findings in October 2006. Today, most lung cancers are found when they are advanced and are more difficult to treat successfully, physicians say. Grannis, Rotter and their I-ELCAP colleagues want to find a reliable way to detect more lung cancers at an early stage to offer patients a better chance at beating the disease. I-ELCAP comprises researchers at 40 institutions in the United States, Europe and Asia who are studying the potential of CT for early lung cancer detection. City of Hope is the only I-ELCAP participating institution in the Los Angeles area. In the study, researchers screened more than 31,500 asymptomatic people who smoked, people who had stopped smoking, those who were exposed to significant secondhand smoke or were exposed to carcinogens, such as radon, in their work. They conducted screenings from 1993 to 2005, and conducted nearly 27,500 repeat screenings between seven and 18 months later. Among participants, 13 percent who underwent a baseline CT and 5 percent of those who had a follow-up CT had a positive result requiring further investigation. Screenings and subsequent biopsies detected lung cancer in 484 participants. Among these patients, 85 percent had stage 1 lung Physicians Frederic W. Grannis Jr., (foreground) and Arnold Rotter, seek out lung cancers while they are cancer (412 of 484). Researchers estimate still in an early stage through their participation in the International Early Lung Cancer Action Program.
M
that 88 percent of these stage 1 patients will survive 10 years. Moreover, the researchers estimated the survival rate to be even higher 92 percent for stage 1 patients who had surgery within a month of diagnosis. However, researchers still must follow the patients to determine the true 10-year survival rate. Another recent, unrelated study of CT to detect lung cancer among current and former smokers found that CT did not appear to increase patients survival. But I-ELCAP investigators believe the body of research must be evaluated further to determine the true value of screening tools. Annual CT screening is a viable way to find lung cancers in people at high risk while the cancers are still curable, said Grannis, clinical associate professor of surgery and a member of City of Hopes Lung Cancer and Thoracic Oncology Program. Aside from saving lives, we also believe its cost-effective. Low-cost CT screening costs less than $350, and treatment for early stage lung cancers usually costs much less than that for late-stage lung cancers. In the U.S., more than 213,000 people are diagnosed annually with lung cancer and more than 160,000 die of the disease each year, according to the American Cancer Society. Information about City of Hopes program is available at www.cityofhope.org/lungscreen. I I I
MARKIE RAMIREZ
Parsons Foundation gift funds new teaching laboratory in graduate school

By Jennifer Healy and Carmen R. Gonzalez
A $750,000 grant from the Ralph M. Parsons Foundation will establish a new teaching laboratory for students at City of Hopes Graduate School of Biological Sciences. The 1,057-square-foot Ralph M. Parsons Foundation Teaching Laboratory will provide students with dedicated research space and sophisticated equipment for training in molecular, cellular, chemical, biochemical and genetic disciplines during their first year, enhancing their ability to begin research projects in their second and subsequent years of study. The laboratory is slated for construction within the upcoming Arnold and Mabel Beckman Center for Cancer
Immunotherapeutics and Tumor Immunology at City of Hope. John Rossi, Ph.D., chair of the Division of Molecular Biology, and dean of the Graduate School of Biological Sciences, noted that the new laboratory will enhance instruction in how to conduct research. The Parsons Foundation teaching laboratory will significantly expand the educational resources available to our students, he said. The facility will allow students to learn basic and advanced laboratory skills through direct, hands-on experience. Our graduate students will be well-prepared to launch their own scientific pursuits and
contribute to City of Hopes overall research enterprise. Dedicated to supporting the efforts of nonprofits across Southern California, the Ralph M. Parsons Foundation has been providing funding since its inception in 1961. In 1976, it became fully independent of the Parsons Company. Over the past 20 years, City of Hope has received grants exceeding $2.5 million from the Parsons Foundation. Most recently, the foundation funded fellowships for students of City of Hopes Graduate School of Biological Sciences. The Parsons Foundation also supported construction of Helford Clinical Research Hospital at City of Hope. I I I
W.M. Keck Foundation supports joint effort to develop advanced therapies against lymphoma
By Kathleen ONeil
Stephen Forman
The W.M. Keck Foundation has awarded investigators at City of Hope and the California Institute of Technology a $450,000 grant to study the molecular mechanisms underlying lymphoma and develop new treatments for it. The pilot grant includes the opportunity to renew funding for as much as $1.55 million through 2010. Lymphoma is a group of cancers of the immune system. It is the fifth most common cancer in the United States and is on the rise. Chemotherapy and radiation cannot cure several types of lymphoma, and many lymphomas recur. The grant supports City of Hope and Caltech scientists who are developing nanotechnology-based therapies to destroy lymphoma cells without harming healthy cells, reducing side effects. Patients would greatly benefit from less-toxic therapies for lymphoma, particularly older patients, who are most often affected and may not be able to tolerate intensive treatments, said
Stephen Forman, M.D., the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at City of Hope and principal investigator of the study. Caltech investigators include Mark Davis, Ph.D., the Warren and Katharine Schlinger Professor of Chemical Engineering, and Scott Fraser, Ph.D., the Anna L. Rosen Professor of Biology, professor of bioengineering and director of the Magnetic Resonance Imaging Center at Caltech. City of Hope investigators include Forman; John Rossi, Ph.D., chair of the Division of Molecular Biology; Andrew Raubitschek, M.D., chair of the Division of Cancer Immunotherapeutics & Tumor Immunology; David Colcher, Ph.D., deputy director of the Department of Radioimmunotherapy Research; Richard Jove, Ph.D., chair of the Division of Molecular Medicine and co-director of the Developmental Cancer Therapeutics Program; and Hua Eleanor Yu, Ph.D.,
professor in the Division of Cancer Immunotherapeutics & Tumor Immunology. The Keck grant complements City of Hopes Specialized Program of Research Excellence, work funded by the National Cancer Institute to improve the detection and treatment of Hodgkins disease and non-Hodgkins lymphoma. Based in Los Angeles, the W.M. Keck Foundation was established in 1954 by the late W.M. Keck, founder of the Superior Oil Company. The foundations grant-making focuses primarily on pioneering efforts in the areas of medical research, science and engineering. I I I
Mark Davis
COURTESY OF CALTECH
MARKIE RAMIREZ
Biotech entrepreneur and business administration dean to serve on City of Hopes national board of directors
By Jennifer Healy
Gail K. Naughton, Ph.D., co-founder and former vice chair of Advance Tissue Sciences, has been named to the national board of directors of City of Hope. Naughton currently serves as dean of the College of Business Administration at San Diego State University (SDSU) and holds more than 90 patents in the field of tissue engineering.
Gail Naughtons biotech background and entrepreneurial spirit make her an ideal fit for our board, said Philip L. Engel, chair of City of Hopes board. She brings a wealth of knowledge, leadership skills and ingenuity that will play a pivotal role in guiding the organization toward its strategic goals. Naughton has served as dean at SDSU since 2002. Prior to that, she spent
Support breast cancer research, treatment and education.
2007 WALK SCHEDULE

Sunday, June 3 Sunday, October 7 Sunday, October 7 Sunday, October 7 Saturday, October 13 Sunday, October 14 Sunday, October 14 Sunday, October 21 Edison, NJ Seattle, WA Phoenix, AZ Washington, DC San Francisco, CA Chicago, IL Philadelphia, PA Los Angeles, CA
Make a difference! Join thousands across the country at Walk for Hope to Cure Breast Cancer. The funds you raise will go directly toward City of Hopes breast cancer research, treatment and education programs. Two million women in the U.S. are being treated for breast cancer One in eight women will be diagnosed with breast cancer in her lifetime.
800-266-7920 www.walk4hope.org/walkinfo
National Sponsors:
more than 15 years at Advance Tissue Sciences, which specialized in engineered skin products for the treatment of chronic wounds. Naughton co-founded the company and was co-inventor of its core technology. She held a variety of management positions during her tenure, including president, chief operating officer, chief scientific officer and principal scientist, and she oversaw the design and development of the worlds first upscaled manufacturing facility for tissue-engineered products. In 2000, Naughton received the 27th annual National Inventor of the Year award from the Intellectual Property Owners Association in honor of her pioneering work in tissue engineering. She began her career in academia, first as an instructor and later as assistant professor at New York University Medical Center, and then as an assistant professor at the City University of New Yorks Hunter York College. Naughton holds a Doctor of Philosophy degree in hematology and a
Masters of Science degree in histology, both from New York University Medical Center. She also received her executive Master of Business Administration degree from UCLA Anderson School of Management, and earned her bachelors degree from St. Francis College in Brooklyn, N.Y. City of Hopes board of directors is composed of 29 members, spanning a range of industries that include finance and health care. I I I
Gail K. Naughton
For more information
COURTSEY OF SAN DIEGO UNIVERSITY
A lasting legacy in immunotherapy

By Carmen R. Gonzalez
Ruth Leaders family has always felt a special bond with City of Hope, giving selflessly of their time and money for decades to support its mission. The bond was recently solidified by Leader a 13-year City of Hope Oceanside, Calif., chapter member who guided a $2 million bequest from the estate of her niece, Diana Chudacoff Levin, in 2006.
The generous Levin gift will benefit the Arnold and Mabel Beckman Center for Immunotherapeutics and Tumor Immunology, an advanced 108,000square-foot translational research facility dedicated to the development of immunotherapy, a treatment that uses the immune system to fight cancer and other life-threatening illnesses. Leader, who lives in Oceanside, Calif., explained that Levins gift was a natural extension of their An artists rendering of The Arnold and Mabel Beckman Center for Cancer Immunotherapeutics and Tumor Immunology familys pride and respect for the organization. It was just something we did. When we thought of The Levin estates $2 million gift represents a substantial helping people, we thought of City of Hope, said Leader. It is contribution toward City of Hopes $60 million fundraising goal for a very special place. the center. Some prior noteworthy gifts include $20 million from Leaders son, Lee, who is the executor of the estate, reflected the Arnold and Mabel Beckman Foundation, a $15 million gift with his mother on how best to honor Levins memory. By from an anomymous donor, a $2 million bequest from longtime supporting the establishment of the Arnold and Mabel Beckman City of Hope supporter Norma Connick, and a $1.5 million Center, they believed the gift would create a legacy of scientific bequest from longstanding backer Marcella S. Schwartz. inquiry that will benefit patients for generations. This generous gift Within the Arnold and Mabel Beckman Center, scientists will will advance City of Hopes explore how cancer cells evade the immune system the bodys ability to create an line of defense while translational and clinical researchers apply unrivaled translational those discoveries to new therapies and evaluate such therapies research center dedicated in clinical trials. The futuristic, five-story facility will stand to bringing the promise of across from Helford Clinical Research Hospital at City of Hope, immunotherapy to encouraging cross-campus collaborations among the faculty. patients everywhere, From left, Diana Levins uncle and aunt, Levins philanthropic nature resulted in gifts for a number of said Michael A. Friedman, Seymour Prell and Ruth Leader, Lorrie worthy causes. Her other passions included a love of travel, with M.D., president and Bernstein and Ocean Hills Chapter President numerous trips to Asia and other exotic locales. Levin, a widow chief executive officer Sheldon Bernstein display a check denoting the generous gift. of her late husband Carl, lived in West Los Angeles. of City of Hope. I I I
M M
MICHAEL BROWN
ILLUSTRATION: PERKINS & WILL
P L A N N I N G
A PHILANTHROPIC SPIRIT
BRIDGING GENERATIONS
By Pat Kramer
Personal loss leads to generous lifelong support

Sophia Sophie Fitzmaurice believes future cancer patients will have the best chances for recovery through ongoing research at City of Hope. And she has committed her own personal resources to back Sophia Fitzmaurice up her belief. The longtime volunteer, a founding member of the Angels of Hope Chapter in Palos Verdes, Calif., recently made a commitment of annual charitable gift annuities totaling $250,000. In recognition, a hospital room in the pediatric unit of Helford Clinical Research Hospital at City of Hope will be named in her honor. Her commitment to biomedical research began in 1953, when she learned that two of her four children suffered from thalassemia, a fatal blood disease. After living through her childrens experiences, Fitzmaurice decided to dedicate her own life to helping other children with serious diseases. During her first visit to campus more than 20 years ago, Fitzmaurice learned of City of Hopes bone marrow transplantation and pediatric cancer programs. Inspired by the work, she devoted herself to backing City of Hope researchers in their quest of cures for devastating illnesses. Her commitment paralleled that of her close friends and neighbors, Irwin and Betty Helford, benefactors of Helford Hospital. On a recent visit to campus, Fitzmaurice visited the laboratory of Michael C. Jensen, M.D., associate professor of Pediatrics and director of the Pediatric Neuro-oncology program, and learned more about an investigative cancer-fighting strategy called adoptive T-cell therapy. Fitzmaurice became interested in a clinical trial now under way for a particularly deadly cancer. City of Hope is so advanced in its medical research, Fitzmaurice said. My son and daughter spent their childhoods and a good part of their adult lives in hospitals and doctors offices. It was their wish that the children they left behind would not have to experience the pain they had, and would be able to live long and healthy lives. I am confident that my gift to City of Hope will be well spent, helping those with cancer and other life-threatening diseases thrive and enjoy a better quality of life. I I I
M
G I F T
Familial bonds have been an integral part of philanthropy at City of Hope since its inception. Whether it is the valued support of a devoted mother who has turned her own personal challenge into a crusade for children everywhere, or a doting grandmother striving to instill her commitment to altruism in her grandson, philanthropic legacies represent a special form of support for the institution.
NEIL RICHARDSON
Throughout his life, 81-year-old Tucson, Ariz., resident and devoted City of Hope supporter Arnold Zuckerman collected postage stamps as a hobby. Now, his philatelic investment is helping to save lives. In preparation for his recent move into a retirement home, the longtime City of Hope supporter sold his prized stamp collection, valued at more than $153,000, and donated the proceeds to City of Hope. He made the gift in memory of his late wife, Lois, and his late mother, Edna, both of whom succumbed to cancer. Lois Zuckerman died in 1997 after battling both breast and lung cancer. Prior to her illness, she served City of Hope as a member of the Fred and Gertrude Rosen Chapter, also located in Tucson. Zuckerman, who recalls the satisfaction he felt when accompanying his wife to chapter meetings and fundraising events during their marriage, also was pleased when the Rosen chapter dedicated a memorial plaque to Lois in memory of her years of faithful service. The plaque is displayed on the Wall of Hope on the Duarte, Calif., campus. Zuckermans mother, Edna, died in 1948 from stomach cancer. Also devoted to charity, she was active in the Hebrew Immigrant Aid Society, which helped Jewish immigrants make their way to America from Europe. His mother also worked with orphaned children in the Chicago area, where Zuckerman was raised. Stamp collecting contributed to a lifelong interest in history, influencing Zuckermans career path. Before retiring to Arizona, he taught history for many years at Truman State University in Kirksville, Mo. His surviving family includes a stepdaughter, Judi Schweitzer. In recognition of Zuckermans generous gift, an elevator in Helford Clinical Research Hospital at City of Hope has been named the Lois B. Zuckerman and Edna Zuckerman Elevator. He hopes his gift will inspire others with valuable collections to consider their own donations to City of Hope. I I I
As a third generation member of a family devoted to philanthropy, Scott Morielli was educated by his late grandmother on the importance of charitable giving. During her final decade of life, Lee Graff instilled in the Lee Graff 37-year-old Morielli her own values of altruism, preparing him for his role as her successor. For 10 years, while helping to run the family company, Morielli would spend each Tuesday with his grandmother, listening to her philanthropic vision. My grandmother loved doing things for others. She was truly selfless and focused on making the world a better place, Morielli said. Graff and her late husband Seymour are iconic figures in City of Hopes history. From 1954 until he died in 1964, Seymour Graff sat on City of Hopes board of directors, and served as president and chair of the board from 1961 to 1964. Lee Graff also served on the institutions board and was named Vice Chair for Life in 1989. The Lee Graff Medical and Scientific Library, which opened in 1984, is another important family contribution. Today, the Lee Graff Foundation continues to fund the Graff Library, known as one of the nations foremost medical research libraries. In addition, the Graffs helped found City of Hopes Merchants Club, which merged with the Professions and Finance Associates in 1995 to become the Apparel Industries Group, now a leading support group. The three groups have raised tens of millions of dollars for the institution since their inceptions. Lee Graff appointed Morielli as executor of both her estate and her foundation prior to her death in March 2005. In this role, Morielli recently designated a $250,000 endowment to support the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics and Tumor Immunology. It was a forward-thinking process, said Morielli. I wanted to ensure this donation went toward furthering immunotherapeutic research and other advanced medical research that City of Hope is leading. In 1933, the Graffs founded their highly successful business, Graff Californiawear, formerly one of the nations largest privatelyheld apparel companies. After her husbands death, Lee Graff assumed the role of company president and chief executive officer. Morielli also served as a vice president of the company. I I I
CITY OF HOPE ARCHIVES
Arnold Zuckerman, Judi Schweitzer (center) and the late Lois Zuckerman
A valued collection becomes a significant donation
COURTESY OF ZUCKERMAN FAMILY
Grandmother spurs a devoted grandsons vision
H O P E
Companies align with City of Hope to save lives

City of Hopes dedicated corporate supporters have helped raise more than $25 million since 1999. These programs generate considerable national awareness for the institutions mission to eradicate devastating diseases. We thank all of the companies that support our lifesaving research, treatment and education efforts through cause-related marketing campaigns.
C A U S E
F O R
During May, Americans can celebrate moms around the nation by joining City of Hope in the fight against breast cancer. Companies nationwide will raise awareness and much-needed funds for City of Hope through products and services linked to the breast cancer theme. Watch for these opportunities to help women everywhere live longer, healthier lives.
3Ms steadfast commitment to City of Hopes mission continues. Since 2004, the companys Post-it Super Sticky Notes Stick Up for the Cause campaign has raised hundreds of thousands of dollars for breast cancer research, treatment and education programs at City of Hope. Specially marked pink-ribbon products, including Post-it Super Sticky Notes and dispensers, special flag pens and highlighters, continue to generate hundreds of thousands of dollars from per-product donations, including their $100,000 sponsorship of City of Hopes Walk for Hope to Cure Breast Cancer. In addition, 3Ms Clean up for the Cause with O-Cel-O scrub sponges campaign generates a 10-cent donation for each specially marked package, with a minimum guaranteed donation of $50,000. Dole Fresh Flowers, the largest producer and marketer of fresh-cut flowers in the United States, aligns with Albertsons in May to help benefit breast cancer research, treatment and education at City of Hope. In honor of Mothers Day,
shoppers may purchase Dole Fresh Flowers breast-cancer awareness flower bouquets at participating locations nationwide. On behalf of the participating retailers, Dole Fresh Flowers donates 5 percent of the purchase price (excluding a freight charge) for every bouquet purchased by the retailer to City of Hope. Dole and Albertsons also will collaborate on a similar promotion again in October 2007. Purchase bouquets in your local Albertsons during Breast Cancer Awareness Month, and help Dole surpass the nearly $80,000 they have raised for the cause since May 2004.
With more than a dozen brands customers know and trust, Sanford, a Newell Rubbermaid company, is a leader in the writing instrument and art supply industry. To help in the fight against breast cancer, Sanford brands Parker, Rolodex, and Paper Mate collectively pledged to raise up to $200,000 through Dec. 31, 2008. For its part, Parker will donate 25 cents from the purchase of every specially marked Jotter pen, up to $50,000. Rolodex is donating $20,000, and sales of individual Paper Mate FlexGrip Pens and Eraser Packs will generate 10-cent-peritem donations, up to $200,000, all benefiting City of Hopes breast cancer research, treatment and education efforts.
Former talk-show host and TV personality Jenny Jones provides simple, healthy recipes and supports breast cancer research with her book, Look Good, Feel Great Cookbook: How Eating Superfoods Can Help You Turn Back the Clock with Over 80 Comfort Food Recipes. To date, $100,000 in profits from the book have been donated to City of Hopes breast cancer research, treatment and education efforts and donation generation efforts continue. Available at bookstores nationwide, this colorful cookbook makes a great Mothers Day gift. I I I
NCI centers
By Alicia Di Rado
UNITE
to market for a cause
The leading cancer centers now have another mission in addition to vanquishing an all-too-prevalent disease.
Thirteen of the nations top-tiered, National Cancer Institutedesignated comprehensive cancer centers have formed the Cancer Research Alliance, a nonprofit organization devoted to securing national cause-related marketing alliances to fund cancer research at the participating organizations. Those organizations include City of Hope, Dana-Farber Cancer Institute, Fox Chase Cancer Center, Fred Hutchinson Cancer Research Center, the Holden Comprehensive Cancer Center at University of Iowa, Arthur C. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill, Lombardi Comprehensive Cancer Center at Georgetown University, the University of Texas M.D. Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Robert H. Lurie Comprehensive Cancer Center at Northwestern University,
Roswell Park Cancer Institute and the University of California, San Francisco Comprehensive Cancer Center. Cause-related marketing is the public association of a forprofit company with a nonprofit organization or cause, both to promote the companys product or service, and to raise money and awareness for the nonprofit. Nonprofit organizations and companies alike have long used cause-related marketing to benefit their brands and impact their bottom lines. According to the International Events Group, corporations in the United States spent more than $1.6 billion on cause-related marketing in 2006 alone. The participating cancer centers recognize the power of cause-related marketing, both as a fundraising tool and as a branding vehicle, said Kevin Koga, associate vice president of communications at City of Hope, who is a staff member of the Cancer Research Alliance. The Cancer Research Alliance is the first organization of its kind to provide both local and national value to participating companies. The Cancer Research Alliance currently is securing national corporate partners and expects the first consumer promotions to begin in 2008. I I I
STANDING BEHIND A CAUSE

Among Americans
Americans believe that corporations need to act responsibly, and they appreciate companies that contribute to important causes, such as the fight against cancer and other serious diseases. The Cancer Research Alliance will link with such corporations.
Source: 2004 Cone Corporate Citizenship Study
86 percent would switch from one brand to another of similar price and quality if that brand were associated with a cause.
I
I 80 percent could name a company that stands out as a strong corporate citizen.
I 75 percent said a companys commitment to a social cause was important when deciding which products or services to recommend to others.
F I R ST P E R S O N : PAT I E N T P RO F I L E
KEN THOMPSON
Industry group provides a
lifesaving referral
Portland, Ore., resident and cancer survivor Ken Thompson was diagnosed with stage 4 multiple myeloma in December 1996 when he was 52 years old. After a successful bone marrow transplant at City of Hope, he has been cancer-free for more than nine years. A former manager in the wholesale grocery industry, Ken was the featured patient speaker at the Pacific Northwest Food Industries Circles 18th annual Harvest Celebration Ball, which was held on Oct. 28, 2006, in Seattle. Now working in real estate, he enjoys horseback riding, hunting, fishing and hot-rod motoring. He and his wife, Rosemary, have two sons, a daughter and six grandchildren.
My doctor called me about my devastating cancer diagnosis the day before Christmas in 1996 and he was not optimistic. He said that while I might survive for another two years, my cancer was terminal and treatment would only keep me comfortable during that time. Initially, I was shocked and angry that something like this could happen to me. Then my anger turned to resolve. I wanted to fight back. And to do so, I knew I had to develop a strong, positive approach. When news of my diagnosis reached my workplace at the time, Alan Jones who is the chief executive officer of United Grocers contacted me. He told me that the grocery industry was a longtime supporter of City of Hope and highly recommended it as the best place for me to go for my treatment. As I made my first appointment for Jan. 2, 1997, my hope began to grow. My wife and I began to feel a sense of calm when we arrived at City of Hope. As we looked around, we noticed many others facing similar situations. It was good to know that we werent alone. After completing my initial tests, I met with my oncologist, Margaret ODonnell, M.D., who explained the protocol for my treatment. I was to receive a tandem stem cell transplant using my own stem cells. This experimental treatment was so new, I was one of the first 60 patients to receive it.
While I had concerns and fears about whether the treatment would be successful, someone always was there to answer my questions or to respond to my physical or emotional needs during those nine months. The care my wife and I received was so wonderful, it was as if I was the hospitals only patient. Before long, I began to feel like the staff of City of Hope was an extension of my own family. It was also comforting to know that nearby on the same campus, researchers were working to find new solutions for treating my cancer, as well as many others. My last transplant occurred on Sept. 25, 1997. I refer to it as my born-again day, because I honestly feel that City of Hope gave me my life back. I also feel grateful to all those who contribute their time and efforts fundraising to support research and treatment at City of Hope. It is inspiring to think of all of the lives they have saved. This past September, I celebrated my ninth year of being cancer-free. Each year, as I acknowledge this special anniversary, I will remember all those people who helped me make it to where I am today. Alan Jones, Joseph Weresch, M.D., of Portland, Dr. ODonnell, and all of the other staff members at City of Hope, and the many friends and family who were there always will hold a special place in my heart. I I I
Ken Thompson and his wife, Rosemary.
COURTESY OF THOMPSON FAMILY
American Cancer Society report
U.S. cancer deaths drop for second consecutive year

By Shawn Le and Alicia Di Rado
Fewer people died of cancer in 2004 than in 2003, marking the second straight year that cancer deaths have declined in the United States, according to a new American Cancer Society report. And City of Hope physicians and researchers are optimistic about the progress.
According to the report, Cancer Statistics 2007, 3,014 fewer people died of cancer in 2004 compared to the previous year. The 2004 data were the latest available. President Nixon declared war on cancer in the early 1970s, and we are finally beginning to see some of the fruits of these efforts, said Robert Figlin, M.D., the Arthur and Rosalie Kaplan Professor of Medical Oncology and chair of the Division of Medical Oncology & Therapeutics Research. Were making great strides in fighting cancer, and each research discovery and novel treatment brings us one step closer to finding cures. The drop in deaths marks the second straight year that deaths from cancer declined: officials reported 369 fewer cancer deaths in 2003 than 2002. American Cancer Society leaders credit improved education about cancer prevention, earlier detection and treatment advances. Death rates linked to most major cancers, including breast, prostate and colorectal cancers, have declined steadily in recent years. And while lung cancer remains the top cancer killer for both genders, the lung cancer mortality rate among women has leveled off, and fewer men are being diagnosed with lung cancer and dying from it.
City of Hope physicians and researchers are contributing to the gains. Researchers are helping to better identify womens risk of developing breast cancer based on genetics, while others are determining which therapies may be most effective in treating specific patients, for example. City of Hope physicians participating in the International Early Lung Cancer Action Program are evaluating computed tomography as a lung cancer screening method to find cancer early among those considered at high risk for the disease. Statistics within certain ethnic groups show room for progress. According to the report, cancer still hits African-Americans particularly hard. And while Latinos, Asian-Americans and Pacific Islanders have slightly lower cancer rates overall than whites, they show a higher risk for cancers that may
be linked to infections, such as liver and cervical cancers, the report indicates. Scientists in the Division of Population Sciences at City of Hope explore cancer diagnosis, treatment, outcome and quality of life among those of different races, ethnicities and other characteristics. The divisions Center of Community Alliance for Research & Education was created in 2006 to address cancer education and control in diverse communities, and seeks interventions that can make a difference in improving cancer outcomes. Despite advances, physicians advise that Americans must still adopt and maintain healthy lifestyles to do all they can to reduce their risk. The American Cancer Society estimates 1,444,920 new cases of cancer will be diagnosed and 559,650 people will die from cancer in 2007. I I I
2 0 07 N AT I O N A L CO N V E N T I O N
Extending
By Fran Rizzi
intergenerational legacies of support
This summer, Southern California will welcome hundreds of volunteers from across the country for the 2007 City of Hope National Convention. This years theme, Building a Future of Hope, symbolizes the host of activities planned to highlight the institutions achievements and profound legacy of support.
This years convention, held at the Beverly Hilton Hotel in Beverly Hills, Calif., from June 23 to 25, will feature opportunities to learn directly about scientific and medical advances, as well as inspirational sessions with City of Hope leaders. The meeting will convene on Saturday, June 23, with presentations from City of Hopes President and Chief Executive Officer Michael A. Friedman, M.D., and outgoing Board Chair Phil Engel. Sundays activities will center around a Day of Discovery, where conventioneers will interact with scientists and clinicians who will share information on their research and treatment efforts, as well as grateful patients, who will discuss their stories of hope and healing. Mondays agenda will include Hope Forum, a series of educational sessions that will focus on fundraising tools and strategies, the traditional Roll Call and a dinner gala. During the evenings gathering, the newly elected board chair, Terry Peets, will address conventioneers. While much of the convention programming will highlight the future, activities also will celebrate the institutions legacy of philanthropy integral to the auxiliary movement. Generations of compassionate and committed families and many others have enabled the institution to flourish and expand, and volunteer leaders who share in this legacy will host each evening of the convention. Saturdays opening events will be co-hosted by Bonnie Fein and her brother, Michael Kaplan, who share their parents unwavering commitment to City of Hope. In the Kaplan familys most recent act of generosity in 2006, they established the Arthur and Rosalie Kaplan Professorship in Medical Oncology. Robert Figlin, M.D., is the first holder of the professorship. Additionally, the lobby of Helford Clinical Research Hospital at City of Hope was named in recognition of another magnanimous gift. Longtime supporters Don Hoffman and Pat Perrott will host Sunday evenings events. Hoffmans father, Irving, served as president of the Merchants Club from 1962 to 1963. Today, Don Hoffman chairs the think tank of the Board of Governors, of which he is a member, and plays a vital role on the City of Hope National Medical Centers board of directors and with the institutions Ambassador Leadership Council. When the Perrott family was touched by leukemia in 1991, its connection to City of Hope was firmly established. At that time, Ed and Pat Perrotts son, Matthew, received a lifesaving bone marrow transplant. Today, he is part of the institutions Speakers Bureau, through which he shares his experience as a cancer survivor and inspires others to join in the battle against the disease. Pat Perrott also is an active member of the Ambassador Leadership Council. On Monday night, Lisa Kaye Fuld, whose mother founded the East End Chapter/Jeanne Kay League of New York, will host the gala event. Today, Fuld serves as co-president of the East End Chapter, and her children, Ryan and Jamie, have founded Teens for Hope, fostering an intergenerational legacy of philanthropy. Further news about this years National Convention will be shared with chapter members in coming weeks. In addition, chapter members may learn more about the event by calling Alan Levey, senior vice president of Development, at 800-872-3872, ext. 26140, or by contacting their local regional development office. I I I
These are just a few of the City of Hope developments that have been making news across the country.
City of Hope experts were featured in several front-page stories about the American Cancer Societys 2007 report on cancer deaths declining for the second consecutive year. Robert Figlin, M.D., Arthur and Rosalie Kaplan Professor of Medical Oncology, was quoted in the Jan. 18 Los Angeles Times, Denver Post and San Jose Mercury News. Smita Bhatia, M.D., M.P.H. and Frederic Grannis, M.D., were quoted in the Jan. 18 Pasadena Star-News, San Gabriel Valley Tribune and Whittier Daily News. The New York Times listed City of Hope as one of the participating centers in the International Early Lung Cancer Action Programs computed tomography screening trial in its Nov. 2 Ask Science online Q&A. Larry Couture, Ph.D., senior vice president, Center for Applied Technology Development, was featured in a Mar. 5 Los Angeles Times story about the curative potential of adult stem cells and the growing private stem cell banking industry. Betty Ferrell, Ph.D., R.N., professor, Department of Nursing Research & Education, was quoted in a front-page Washington Post article on March 12 about racial disparities and choices in end-of-life care and a Feb. 15 USA Today story about the spiritual needs of cancer patients based on an editorial she wrote in the Journal of Clinical Oncology.
The Associated Press ran a story Dec. 13 about City of Hopes collaboration with Sangamo Biosciences to develop a novel immunotherapeutic treatment for brain cancer. The article also was featured in MSN Money, Businessweek.com and the Houston Chronicle. The collaboration also was featured by Barrons on Dec. 18 and the Los Angeles Business Journal on Jan. 8. Singer and actress Olivia Newton-John was interviewed about her breast self-exam kit on Reuters and the Washington Post on Oct. 20, CBSs The Early Show on Oct. 30 and Chicagos WLS-TVs ABC7 News on Oct. 23. A portion of proceeds from kit sales benefit City of Hope. A segment on City of Hopes Spirit of Life event honoring Charles Goldstuck, president and chief operating officer of Bertelsmann Music Group, aired Oct. 21 on Extra! Writer Liz Smith also mentioned the event in her Oct. 13 column, which appeared in the New York Post, Star-Ledger and other outlets. Stephen Forman, M.D., Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, and Defu Zeng, M.D., assistant professor, Department of Diabetes, Endocrinology & Metabolism and Division of Hematology & Hematopoietic Cell
Transplantation, were quoted in an April 11 Los Angeles Times article about using stem cell transplantation to treat type 1 diabetes. Theodore Krontiris, M.D., Ph.D., executive vice president, Medical and Scientific Affairs, was named one of Los Angeles most influential people in science in the Dec. 2006 issue of Los Angeles Magazine. A front page story in the Dec. 24 San Francisco Chronicle on the BALCO steroid scandal featured commentary from Barry Forman, M.D., Ph.D., Ruth B. and Robert K. Lanman Chair in Gene Regulation & Drug Discovery Research, about his strategy for testing and detecting performanceenhancing drugs. An April 11 U.S. News & World Report story about using blood stem cells to treat type 1 diabetes included comments from Defu Zeng, M.D., assistant professor, Department of Diabetes, Endocrinology & Metabolism and Division of Hematology & Hematopoietic Cell Transplantation. Kathleen Kane, executive vice president of Development and External Affairs, was interviewed by KABC-TV (Los Angeles) about making informed decisions when supporting charitable causes. The segment, which identified City of Hope as one of the finest research and
medical facilities in the nation, aired on Nov. 29, Dec. 2 and Dec. 3. Forbes.com featured City of Hope as part of its annual ranking of the top 200 charities nationwide. The full list appeared online on Nov. 22. I I I
I N
T H E
N E W S
NUMBERS
T O K N O W
Support for lymphoma research

City of Hope supporters raised more than $630,000 to support lymphoma research at the Marc Goodman Lymphoma Research Golf Tournament on Sept. 11.
Held at the Wilshire Country Club in Los Angeles, the tournament and dinner celebrated the life of Goodman, a Discovery Channel executive who passed away from nonHodgkins lymphoma in 2005 at age 46. In addition, the more than 300 gathered guests honored Stephen J. Forman, M.D., Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, for his pioneering work in treating lymphoma. Dinner guests enjoyed an elegant meal prepared by world-renowned chefs Nobu Matsuhisa and Shigefumi Tiachibe, as well as a
THOMAS BROWN
CITY OF HOPE MEDICAL CENTER

800-423-7119
PATIENT REFERRAL LINE

(for patient referral inquiries) 800-826-4673
GIFT PLANNING
800-232-3314
CITY OF HOPE REGIONAL DEVELOPMENT OFFICES:

LOS ANGELES DEVELOPMENT HEADQUARTERS 800-544-3541 MIDWEST REGION
Chicago Regional Headquarters
800-779-5893 NORTHEAST REGION

Philadelphia Regional Headquarters
800-344-8169 NORTHWEST REGION

San Francisco Regional Headquarters
live auction hosted by golf pro and author David Feherty. Major supporters included the Goodman and Eller families, Discovery Networks, A & E Television Networks, the Milken Family Foundation and Lionsgate. Presenting Forman (far right) with his award at the dinner were Bennett Goodman, Marc Goodmans brother, and his widow, Elissa. I I I
800-732-7140
Seattle Office
Hardware/Homebuilding Industry kicks off annual fundraising campaign by honoring Foote

From left, Kevin Courtney, senior vice president, National Accounts of USG Corporation, congratulates USG Corporation chairman and chief executive officer William C. Foote (with his wife, Kari) as he receives The Spirit of Life Award at the Hardware/Homebuilding Industrys annual fundraising kickoff campaign, held in Orlando, Fla., on Feb. 7. Hundreds of the industrys supporters gathered to honor Foote and to celebrate a $500,000 kickoff total for the industry groups 2007 campaign, which is expected to raise more than $3 million. Since its inception more than two decades ago, the industry group has raised more than $143 million for City of Hope. I I I
M
800-934-9196 SOUTHEAST REGION

Florida Office (Fort Lauderdale)
800-584-6709 SOUTHWEST REGION

Los Angeles Development Headquarters
800-544-3541
Desert Communities Office (Cathedral City, Calif.)
800-732-7121
Phoenix Office
800-732-7309
San Diego Office
888-805-8911
S TAY I N G I N T O U C H
You may have received this fundraising communication because you previously received services at City of Hope National Medical Center. If you do not wish to receive such communications in the future, send a written request to the following address: City of Hope 1055 Wilshire Blvd. Los Angeles, CA 90017 Attn.: Publications Manager, Communications
MEA CULPA
In the Winter 2007 issue of City News, the article Philanthropists make the right connections mentioned individuals who have raised funds on behalf of the Hope Connection Chapter. The name of Jay Oken, a former City of Hope patient and co-chair of the annual Hope Connection/Spencer Shiffman Charity Golf Tournament, was inadvertently omitted. Hope Connection Chapter President Michele Oken is Jays sister. I I I
CA L E N DA R
To find out about events taking place across the country that support City of Hope, visit our Web site at www.cityofhope.org/calendar. For details about activities happening in your area, please contact your nearest City of Hope Regional Development Office.
JANET JORDAN
An ounce of
By H. Chung So
Many factors influence well-being, but daily habits can play a role in safeguarding health and even lowering the risk of cancer and other diseases. This column includes tips from City of Hope experts on making good lifestyle choices.
I Hit the treadmill: And skip more desserts, too. Two recent reports by the American Cancer Society (ACS) suggest that men who maintain a healthy weight are less likely than overweight men to develop prostate cancer and die from it. To achieve and maintain a healthy weight, the ACS experts suggest watching your caloric consumption and engaging in at least 30 minutes of physical activities five days a week. I Strike preemptively against a common cancer: Colorectal cancer is the third most common cancer in the United States, but experts agree it is indeed preventable. Regular screenings can detect colon polyps before they ever develop into cancer, and removing these growths can prevent the disease. Lifestyle choices may also reduce risk, including regular exercise, a diet high in fiber, fruits and vegetables, and moderating alcohol intake. I Choose your cover: Are you a sun worshipper? Warmer weather may lure you outdoors, but be sure to protect your skin. The message bears repeating: the suns ultraviolet rays may cause skin to wrinkle, develop age spots and, even worse, lead to skin cancer. To defend against the harmful rays, regularly apply a sunscreen with an SPF of 15 or higher before going outdoors and limit exposure to the sun particularly between the peak hours of 10 a.m. to 2 p.m., when rays are strongest. I I I
Get the latest news about City of Hope with just a click of your mouse.
Subscribe to eHope, our monthly online newsletter, by visiting www.cityofhope.org/newsletters. Once you submit your e-mail address, well place you on our list.
T O
Y O U R
prevention
H E A L T H
Did you know that...

up to 65 cents of every dollar in your Individual Retirement Account (IRA) may go to taxes?
Individual IRA distributions can be subject to income tax as high as 35%. Additionally, if an heir inherits the IRA it may be subject to estate tax. By making an IRA Charitable Rollover directly from your IRA to City of Hope, BOTH OF THESE TAXES CAN BE AVOIDED. The new Pension Protection Act allows you to contribute part of your IRA to charity without paying federal income taxes on the withdrawal through December 31, 2007.*
Specifics and Benefits:

Must be age 70 1/2 or older. You can donate up to $100,000 per year in 2006 and 2007. Your donation may be counted toward the required minimal distribution for tax-deferred retirement accounts in the year the gift is made. The IRA Charitable Rollover applies to outright gifts only. A gift from your IRA will not generate federal taxable income or a tax deduction. Its easy Simply instruct your IRA custodian to transfer funds directly to City of Hope. For further information, please contact the Gift Planning Department at 800-232-3314.
*Confer with your advisor regarding your options as differing state tax laws may affect your plans.
www.cityofhope.org/giftplanning
1055 Wilshire Boulevard Los Angeles CA 90017 800-260-HOPE (4673) citynews@coh.org
Nonprofit Organization U.S. Postage PAID Los Angeles, CA Permit No. 5004
www.cityofhope.org
DELIVER TO:
ADDRESS SERVICE REQUESTED

If your address is incorrect, or you are receiving duplicate copies of this publication, please update the label and mail to City News, 1055 Wilshire Blvd., Los Angeles, CA 90017. You can also call 800-544-3541, ext. 26120, or e-mail citynews@coh.org. By giving the code number that appears above your name, your request can be processed quickly. Thank you for helping us to be more efficient in communicating how your support is touching millions of lives.
J02-13099.sr.Spring07.115M Printed on recycled paper

CN Spring 2007

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

CN Spring 2007

Uploaded by

Copyright:

Available Formats

A Q UA RT E R LY P U B L I C AT I O N O F C I T Y O F H O P E

Whats in your DNA?

Honoring decades of inspirational service

Exploring the macro and micro

CITY NEWS SPRING 2007

VOLUME 18 NUMBER 2 SPRING 2007

Whats in your DNA? Nature and nurture link to cancer risk

Good tasting and good for you

Delivering a one-two punch

A tiny idea with huge implications

Vaccine may ward off CMV invaders

Biotech entrepreneur joins City of Hope board

A lasting legacy in immunotherapy: Diana Chudacoff Levin

Building a future of hope: The 2007 National Convention

An ounce of prevention: Keeping healthy

CITY NEWS SPRING 2007 I 1

2 I CITY NEWS SPRING 2007

along from mother and father to son or daughter.

CITY NEWS SPRING 2007 I 3

What links within

4 I CITY NEWS SPRING 2007

CITY NEWS SPRING 2007 I 5

The family tree

6 I CITY NEWS SPRING 2007

CITY NEWS SPRING 2007 I 7

8 I CITY NEWS SPRING 2007

MUSHROOMS MAY SUPPRESS ESTROGEN, DETER BREAST CANCER

ILLUSTRATION: BECKY HEAVNER

CITY NEWS SPRING 2007 I 9

AND GOOD FOR YOU,TOO

10 I CITY NEWS SPRING 2007

ILLUSTRATION: RANDY LYHUS

John Zaia and Amrita Krishnan

CITY NEWS SPRING 2007 I 11

12 I CITY NEWS SPRING 2007

ILLUSTRATION: JEFFREY PELO

Promising vaccine may ward off CMV invaders

MEDICAL RESOURCES PLUS

14 I CITY NEWS SPRING 2007

Finding the truth within

CITY NEWS SPRING 2007 I 15

Homing in on a deadly cancer

16 I CITY NEWS SPRING 2007

Parsons Foundation gift funds new teaching laboratory in graduate school

CITY NEWS SPRING 2007 I 17

Support breast cancer research, treatment and education.

2007 WALK SCHEDULE

18 I CITY NEWS SPRING 2007

For more information

COURTSEY OF SAN DIEGO UNIVERSITY

A lasting legacy in immunotherapy

CITY NEWS SPRING 2007 I 19

ILLUSTRATION: PERKINS & WILL

Personal loss leads to generous lifelong support

20 I CITY NEWS SPRING 2007

A valued collection becomes a significant donation

CITY NEWS SPRING 2007 I 21

COURTESY OF ZUCKERMAN FAMILY

Grandmother spurs a devoted grandsons vision

Companies align with City of Hope to save lives

22 I CITY NEWS SPRING 2007

to market for a cause

STANDING BEHIND A CAUSE